Opinion|Videos|November 18, 2026

Case-Based Discussion: Treatment Selection for Biochemical First Relapse in Relapsed/Refractory Multiple Myeloma

In the first case-based discussion, faculty evaluate treatment options for a 67-year-old man with standard-risk multiple myeloma experiencing a slow biochemical first relapse after one prior line of therapy consisting of bortezomib, lenalidomide, and dexamethasone, autologous stem cell transplantation, and lenalidomide maintenance.

Episodes in this series

In the first case-based discussion, faculty evaluate treatment options for a 67-year-old man with standard-risk multiple myeloma experiencing a slow biochemical first relapse after one prior line of therapy consisting of bortezomib, lenalidomide, and dexamethasone, autologous stem cell transplantation, and lenalidomide maintenance. The patient is anti-CD38 antibody-naive, has preserved organ function, and remains active and independent, but lives 90 minutes from the treatment center, making frequent visits burdensome for his family. Faculty discuss potential approaches, including daratumumab-based combinations with iberdomide or other partners, as well as CAR T-cell therapy and bispecific antibodies. The discussion explores whether T-cell-redirecting therapy should be used at first relapse or whether a CELMoD-based regimen could provide disease control while allowing time to plan subsequent treatment. Faculty weigh disease biology, depth and durability of response, toxicity risks, monitoring requirements, caregiver support, and treatment logistics. The panel emphasizes shared decision-making and individualizing therapy to balance disease control, quality of life, and future treatment options.


Related to this article